Biopharmaceutical Neurocrine Biosciences has completed recruitment in the phase IIb clinical trial (Kinect Study) of its proprietary Vesicular Mono-Amine Transporter 2 compound, NBI-98854. The final subject will randomize this week.

The design of this 12-week phase IIb study is a randomized, parallel, double-blind, placebo-controlled trial of 120 subjects with moderate to severe tardive dyskinesia and underlying schizophrenia or schizoaffective disorder. Data from the placebo-controlled portion of the trial is expected in approximately 10 weeks.